I don't remember seeing SELDI used for pancreatic cancer detection before:
>>SELDI approach for biomarker identification in the diagnosis of pancreatic adenocarcinoma
Jens Koopmann, Zhen Zhang, Nicole White, Jason Rosenzweig, Neal Fedarko, Sanjay Jagannath, Marcia I. Canto, Charles J. Yeo, Ralph H. Hruban, Daniel W. Chan, Michael Goggins, Department of Pathology, Johns Hopkins Hospital, Baltimore, MD; Department of Medicine (Geriatrics), Johns Hopkins Bayview Medical Center, Baltimore, MD; Department of Medicine (Gastroenterology), Johns Hopkins Hospital, Baltimore, MD; Department of Surgery, Johns Hopkins Hospital, Baltimore, MD.
Adenocarcinoma of the pancreas is currently the fifth leading cause of cancer related deaths in the United States. The dismal prognosis (overall five year survival rate of <5%) is owned to the usually advanced stage of the disease at presentation. New biomarkers to enable early detection of pancreatic adenocarcinoma are needed. In an approach to identify such markers we performed SELDI (surface enhanced laser desorption/ionization) Proteinchip (Ciphergen Biosystems) analysis on 180 serum samples. 60 specimens each from patients with pancreatic adenocarcinoma, other pancreatic diseases (pancreatitis, pancreatic cysts, cystadenomas, neuroendocrine tumors, intraductal papillary mucinous neoplasms, ampullary adenomas) and healthy controls from the Johns Hopkins Medical Institutions were analyzed using IMAC-Cu Proteinchip surfaces after fractionation via anion exchange chromatography to increase protein signal yield. Proteinchips were read on a PBSII mass spectrometer (Ciphergen Corp.). The resulting proteomic profiles were analyzed using the component analysis and bootstrap modules of the ProPeak software package (3Z Informatics). Using data derived from the analysis of one fraction (pH 9/flowthrough) we were able to identify a set of four protein peaks (panel PC-A) that separated pancreatic adenocarcinoma from normal controls with a sensitivity of 83% (48/59) and specificity of 85% (50/58). An independent set of protein peaks (panel PC-B) was able to differentiate between pancreatic adenocarcinoma and pancreatitis with 70% sensitivity (41/58) and 85% specificity (22/26). CA 19-9 levels, as the current standard biomarker for pancreatic cancer, were available for a subgroup of the samples (27/60 disease controls, 42/60 cancers). CA19-9 provided a diagnostic sensitivity of 64% and specificity of 85% for pancreatic adenocarcinoma in comparison. These findings illustrate the potential of the SELDI Proteinchip approach for the diagnosis of pancreatic adenocarcinoma. Additional studies, using a combination of data derived from the analysis of more serum fractions and Proteinchip surfaces into a composite index, could further improve the diagnostic accuracy. <<
Cheers, Tuck |
